Abstract 5529
Background
The treatment of mCRPC is a major medical challenge. The beta-emitting Lu-177-PSMA radioligand therapy (RLT) is a new option but its antitumor effect can decrease over time. The aim of this retrospective analysis was to investigate safety and efficacy of the alpha emitting Ac-225-PSMA-617 RLT in mCRPC after Lu-177-PSMA failure.
Methods
At data analysis 03/19 18 patients (pts) underwent Ac-225-PSMA-617 RLT between 10/17 and 12/18. All pts had previously received second line antihormonal treatment and 17/18 pts taxane based chemotherapy. All pts had shown progression after Lu-177-PSMA therapy (median 2 cycles). High PSMA-expression of the tumor lesions in PSMA-PET/CT before Ac-225-PSMA-617 was mandatory. Pts were treated at 8 weekly intervals until progression or intolerable side effects. Prostate-specific antigen (PSA) and blood cell count were measured every 2-3 weeks. We report updated data of hematological and non-hematological side effects, biochemical response and a subgroupanalysis.
Results
A total of 36 cycles of Ac-225-PSMA-617 (median dose 8 MBq, range 4,4–12.8) were applied. 7 pts received only 1 cycle, 5 pts 2 cycles, 5 pts 3 cycles and 1 patient 4 cycles. Baseline PSA was 822 ng/ml (range 49–4073). ECOG score was grade 0, 1 and 2 in 3, 13 and 2 pts. 15/18 pts showed any PSA-decline, 5/18 a PSA-decline of more than 50% and 3 pts no PSA-decline at any time. 6 weeks after treatment 12/18 showed any PSA decline and 4/18 a PSA-decline of > 50%. Grade 1 xerostomia occurred in 17 and grade 2 in 1 patient. 6/18 pts (33%) requested to stop treatment due to xerostomia. 2 pts developed grade 2 renal insufficiency, 5 pts grade 3-4 anemia, 2 pts grade 3-4 thrombocytopenia and 2 pts 3-4 leucopenia. 7/18 pts died during the observation period (median overall survival 9,6 months). The PSA-progression free survival was 1,3 months. In a subgroupanalysis of 9 pts with a rapid progression under a previous Lu-177-PSMA treatment 7 pts achieved any PSA-decline and 4 pts a decline of more than 50%.
Conclusions
In this small cohort Ac-225-PSMA-617 RLT showed antitumor effect in mCRPC after Lu-177-PSMA failure even after rapid tumour progression. However, treatment had to be stopped in one third of the pts due to xerostomia.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1908 - Androgen Receptor (AR) Aberrations in Patients (Pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treated With Apalutamide (APA) Plus Androgen Deprivation Therapy (ADT) in TITAN
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4058 - 68Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic castration resistant prostate cancer patients
Presenter: Anouk de Jong
Session: Poster Display session 3
Resources:
Abstract
2226 - Spatial-Temporal Change in Quantitative Total Bone Imaging (QTBI) and Circulating Tumor Cells (CTCs) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide (ENZA)
Presenter: Glenn Liu
Session: Poster Display session 3
Resources:
Abstract
5795 - Efficacy of Enzalutamide in Hormone-sensitive Metastatic Prostate Cancer: Clinical Utility of 18F-Choline PET and Whole Body MRI.
Presenter: Susanne Osanto
Session: Poster Display session 3
Resources:
Abstract
899 - Urine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result
Presenter: Jungreem Woo
Session: Poster Display session 3
Resources:
Abstract
3094 - Circulating tumor cell (CTC) genomic landscape in neuroendocrine prostate cancer (NEPC) by single cell copy number analysis
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
2527 - Circulating Tumor Cells (CTC) count and Prostate-Specific Antigen (PSA) response measures in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients (pts) treated with Docetaxel (Doc)
Presenter: Rebeca Lozano Mejorada
Session: Poster Display session 3
Resources:
Abstract
6106 - Assessing the clinical relevance of drug–drug interactions (DDI) with darolutamide (DARO)
Presenter: Christian Zurth
Session: Poster Display session 3
Resources:
Abstract
2237 - KEYNOTE-921: phase 3 study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
2241 - KEYNOTE-641: Phase 3 Study of Pembrolizumab (pembro) Plus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: Julie Graff
Session: Poster Display session 3
Resources:
Abstract